News|Articles|May 5, 2026

Texas physician convicted for illegally distributing more than a million pills; semaglutide cuts heavy drinking; hantavirus kills three on Atlantic cruise ship – Morning Medical Update

Fact checked by: Keith A. Reynolds
Listen
0:00 / 0:00

Key Takeaways

  • A federal jury found Barbara Marino, MD guilty of conspiracy and distribution after prescribing >1 million oxycodone, hydrocodone, and carisoprodol pills without legitimate medical purpose.
  • Prosecutors described systematic co-prescribing of opioid–carisoprodol “cocktails” to >99% of patients, typically at the strongest short-acting doses, with patient recruitment by street-level dealers.
SHOW MORE

The top news stories in medicine today.

Texas physician convicted for running pill mill out of cash-only Houston strip mall

Barbara Marino, M.D., prescribed opioids to ‘almost every patient she saw,’ including a woman in her third trimester of pregnancy.

A federal jury has convicted a Texas physician for unlawfully distributing more than a million pills of oxycodone, hydrocodone and the muscle relaxer carisoprodol from a cash-only clinic in a Houston strip mall.

Barbara Marino, MD, 65, of Tomball, was the sole prescribing physician at Angels Clinica, where street-level drug dealers brought patients in exchange for prescriptions that were then filled at local pharmacies and resold on the street. Prosecutors said Marino prescribed the dangerous combination of an opioid and carisoprodol to more than 99% of her patients, almost always in the strongest short-acting doses available and received more than $400,000 in less than a year for writing prescriptions that lacked a legitimate medical purpose. Among her patients was a woman in her third trimester of pregnancy, whose OB/GYN testified at trial about the dangers of the drug cocktail Marino prescribed her. Marino was convicted of one count of conspiracy to distribute a controlled substance and four counts of distributing a controlled substance, each carrying a maximum sentence of 20 years in prison.

GLP-1s reduce heavy drinking

A clinical trial found weekly semaglutide reduced heavy drinking days by 41% in patients with obesity and alcohol use disorder.

Weekly injections of semaglutide reduced heavy drinking days by 41.1% in patients with alcohol use disorder and obesity — a 13.7 percentage point greater reduction than placebo — according to the first randomized controlled trial to test a GLP-1 receptor agonist specifically in this population, published in The Lancet. The 26-week trial, led by researchers at Copenhagen University Hospital with National Institutes of Health (NIH) collaboration, enrolled 108 treatment-seeking patients who received either semaglutide or placebo alongside standard cognitive behavioral therapy. Blood-alcohol biomarkers supported the self-reported drinking data, and the drug's number needed to treat was 4.3, comparing favorably to approved alcohol use disorder medications, which generally require treating seven or more patients to see one benefit. Side effects were mild and transient, primarily gastrointestinal.

"Very few medications are currently approved for alcohol use disorder, and these are vastly underutilized," said NIAAA Director George Koob, Ph.D., a study co-author. Larger and longer trials are needed to confirm the findings.

What is Hantavirus? The virus killed 3 aboard an Atlantic cruise ship

Three passengers died and several others fell ill aboard the MV Hondius, an Atlantic cruise ship, in a suspected outbreak of the rare rodent-borne virus.

A suspected hantavirus outbreak aboard a Dutch cruise ship, the MV Hondius, has killed three passengers and left several others ill. Hantavirus is a family of rodent-borne viruses most commonly contracted when dried droppings, urine or saliva from infected animals become airborne — typically during cleaning or disturbing areas where rodents have nested.

The virus causes two syndromes: hantavirus pulmonary syndrome, the respiratory form most common in North and South America, carries a fatality rate of roughly 40%; the other primarily attacks the kidneys. Early symptoms resemble influenza and appear one to eight weeks after exposure, making diagnosis in the first 72 hours difficult; respiratory deterioration can follow rapidly.

There is no specific antiviral treatment, care is supportive and severe cases may require mechanical ventilation. Person-to-person transmission is rare.

The World Health Organization (WHO) said the risk to the general public remains low, with one confirmed case identified in a British passenger hospitalized in South Africa and five others under investigation.

Infection Control Today has more: Hantavirus: What the public and health care professionals should know